Number of Shares] Ikena Oncology, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • March 22nd, 2021 • Ikena Oncology, Inc. • Biological products, (no disgnostic substances) • New York
EMPLOYMENT AGREEMENTEmployment Agreement • March 22nd, 2021 • Ikena Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (this “Agreement”) is made between Ikena Oncology, Inc., a Delaware corporation (the “Company”), and _____________________ (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreements and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated ______ (the “Prior Agreement”), and (ii) any offer letter, employment agreement or severance agreement.
FORM OF DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • March 22nd, 2021 • Ikena Oncology, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ] by and between Ikena Oncology, Inc., a Delaware corporation, together with its subsidiaries, (the “Company”), and [Director] (“Indemnitee”).
